NASDAQ:STIM Neuronetics (STIM) Stock Price, News & Analysis $1.17 +0.09 (+8.33%) (As of 11/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Neuronetics Stock (NASDAQ:STIM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neuronetics alerts:Sign Up Key Stats Today's Range$1.08▼$1.1850-Day Range$0.73▼$1.1952-Week Range$0.66▼$5.07Volume197,419 shsAverage Volume246,856 shsMarket Capitalization$35.46 millionP/E RatioN/ADividend YieldN/APrice Target$4.67Consensus RatingModerate Buy Company OverviewNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Read More… This is treason (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Neuronetics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks65th Percentile Overall ScoreSTIM MarketRank™: Neuronetics scored higher than 65% of companies evaluated by MarketBeat, and ranked 371st out of 974 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingNeuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuronetics has only been the subject of 3 research reports in the past 90 days.Read more about Neuronetics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($0.87) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neuronetics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.35% of the outstanding shares of Neuronetics have been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently increased by 26.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.35% of the outstanding shares of Neuronetics have been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently increased by 26.08%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment0.71 News SentimentNeuronetics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Neuronetics this week, compared to 2 articles on an average week. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have bought 7,244.65% more of their company's stock than they have sold. Specifically, they have bought $175,170.00 in company stock and sold $2,385.00 in company stock.Percentage Held by InsidersOnly 9.80% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neuronetics' insider trading history. Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address STIM Stock News HeadlinesHead to Head Review: Neuronetics (NASDAQ:STIM) vs. Retractable Technologies (NYSE:RVP)November 5 at 1:51 AM | americanbankingnews.comNeuronetics, Inc. (NASDAQ: STIM) Amends Registration Rights Agreement with Madryn Asset Management LP November 3, 2024 | americanbankingnews.comI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. November 8, 2024 | Porter & Company (Ad)Neuronetics to Unveil Q3 2024 Financial ResultsOctober 31, 2024 | msn.comNeuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference CallOctober 29, 2024 | globenewswire.comNeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with DepressionOctober 14, 2024 | globenewswire.comNeuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder MeetingsOctober 4, 2024 | prnewswire.comBrainsWay: More Cash, More UncertaintyOctober 1, 2024 | seekingalpha.comSee More Headlines STIM Stock Analysis - Frequently Asked Questions How have STIM shares performed this year? Neuronetics' stock was trading at $2.90 at the beginning of 2024. Since then, STIM stock has decreased by 59.7% and is now trading at $1.17. View the best growth stocks for 2024 here. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) released its quarterly earnings results on Monday, August, 12th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.06. The company had revenue of $16.45 million for the quarter, compared to the consensus estimate of $18.76 million. Neuronetics had a negative trailing twelve-month return on equity of 109.00% and a negative net margin of 45.06%. When did Neuronetics IPO? Neuronetics (STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. Who are Neuronetics' major shareholders? Top institutional investors of Neuronetics include GSA Capital Partners LLP (0.26%). Insiders that own company stock include Cannell Capital Llc, Keith J Sullivan, Stephen Furlong, Robert Cascella, William Andrew Macan, Glenn P Muir and Bruce Joseph Shook. View institutional ownership trends. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), General Electric (GE), Intel (INTC), Bank of America (BAC) and Nokia Oyj (NOK). Company Calendar Last Earnings8/12/2024Today11/08/2024Next Earnings (Confirmed)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:STIM CUSIPN/A CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees180Year FoundedN/APrice Target and Rating Average Stock Price Target$4.67 High Stock Price Target$8.00 Low Stock Price Target$3.00 Potential Upside/Downside+300.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,190,000.00 Net Margins-45.06% Pretax Margin-45.06% Return on Equity-109.00% Return on Assets-31.72% Debt Debt-to-Equity Ratio2.38 Current Ratio2.58 Quick Ratio2.37 Sales & Book Value Annual Sales$71.35 million Price / Sales0.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book0.99Miscellaneous Outstanding Shares30,310,000Free Float27,337,000Market Cap$35.31 million OptionableOptionable Beta2.21 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:STIM) was last updated on 11/8/2024 by MarketBeat.com Staff From Our Partners“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCan Trump Make Housing Great Again?Trump won. But can he undo the damage the Democrats have inflicted on this nation? Under Biden, inflatio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.